NCT00002199已完成3 期
A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.
Glaxo Wellcome2 个研究点 分布在 1 个国家目标入组 550 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 550
- 试验地点
- 2
研究概览
简要总结
To compare the safety, tolerance, early antiviral activity, and durability of antiviral response of the lamivudine (3TC)/zidovudine (ZDV)/1592U89 arm versus the 3TC/ZDV/indinavir (IDV) arm. To determine the effect of the two arms on clinical efficacy as determined by the occurrence of new CDC, defined class B/C events, survival, medical resource utilization, and the development of plasma viral genotypic and phenotypic resistance.
详细描述
In this international study, 550 patients are randomized (225 per arm) to receive Combivir in combination with 1592U89 or indinavir. If after 16 weeks (and every 8 weeks thereafter until week 48) a patient has HIV-1 RNA >= 400 copies/ml (by PCR on two occasions >= 1 week and < 4 weeks apart), the patient has the option to switch to open-label therapy consisting of indinavir, 1592U89, and Combivir.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •GM-CSF, G-CSF, and erythropoietin.
- •Concurrent Treatment:
- •Local treatment for Kaposi's sarcoma.
- •Patients must have:
- •HIV-1 infection documented by a licensed HIV-1 antibody ELISA and confirmed by Western blot detection of HIV-1 antibody or positive HIV-1 blood culture.
- •CD4+ cell count >= 100 cells/mm3 within 14 days prior to study drug administration.
- •HIV-1 RNA >= 10,000 copies/ml within 14 days prior to study drug administration.
- •No active diagnosis of AIDS according to the 1993 Centers for Disease Control (CDC) AIDS surveillance definition (excluding CD4+ cell counts < 200 cells/mm3).
- •Signed, informed consent from parent or legal guardian for patients under 18 years of age.
排除标准
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded:
- •Malabsorption syndrome or other gastrointestinal dysfunction that may interfere with drug absorption.
- •Serious medical conditions such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction that would compromise the safety of the patient.
- •Concurrent Medication:
- •Cytotoxic chemotherapeutic agents.
- •Agents with documented anti-HIV-1 activity in vitro.
- •Foscarnet.
- •Immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide, or interferons.
- •Terfenadine, astemizole, cisapride, triazolam, midazolam, and ergotamine/dihydroergotamine.
- •Concurrent Treatment:
- •Radiation therapy.
- •Other investigational treatments. NOTE:
- •Treatments available through treatment IND or other expanded access programs are the exception and evaluated individually.
- •Patients with the following prior conditions are excluded:
- •History of relevant pancreatitis or hepatitis in the last 6 months.
- •Prior Medication:
- •Cytotoxic chemotherapeutic agents within 30 days of study drug administration.
- •Prior antiretroviral therapy.
- •HIV vaccine dose within 90 days of study drug administration.
- •Immunomodulating agents such as systemic corticosteroids, interleukins, or interferons within 30 days of study entry.
- •Prior Treatment:
- •Radiation therapy within 30 days of study drug administration.
- •Current alcohol or illicit drug use that may interfere with patient compliance.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 DrugsHIV InfectionsNCT00002391Glaxo Wellcome
已完成
3 期
Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.HIV InfectionNCT01237444Pedro Cahn417
已完成
3 期
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected PatientsHIV InfectionNCT00234910Abbott152
终止
3 期
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19COVID-19NCT04889040Hoffmann-La Roche216
已完成
3 期
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing RegimenHepatitis C Virus InfectionNCT02822794Gilead Sciences117